After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
VRNA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Verona Pharma Plc ADR is $5.89B. A total of 1.12 million shares were traded on the day, compared to an average of 1.32M shares.
In the most recent transaction, ZACCARDELLI DAVID sold 640,264 shares of VRNA for 5.01 per share on Dec 05 ’24. After the transaction, the President and CEO now owns 14,367,552 company shares. In a previous transaction on Dec 06 ’24, ZACCARDELLI DAVID sold 162,800 shares at 5.01 per share. VRNA shares that President and CEO owns now total 14,204,752.
Among the insiders who sold shares, ZACCARDELLI DAVID disposed of 67,608 shares on Dec 04 ’24 at a per-share price of $5.00. This resulted in the President and CEO holding 15,007,816 shares of VRNA after the transaction. In another insider transaction, Hahn Mark W sold 640,048 shares at $5.01 per share on Dec 05 ’24. Company shares held by the Chief Financial Officer now total 13,477,464.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, VRNA has a high of $69.80 and a low of $11.39.
As of this writing, VRNA has an earnings estimate of -$0.03 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.02 per share and a lower estimate of -$0.05.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. VRNA’s latest balance sheet shows that the firm has $148.38M in Cash & Short Term Investments as of fiscal 2021. There were $5.81M in debt and $33.42M in liabilities at the time. Its Book Value Per Share was $2.42, while its Total Shareholder’s Equity was $148.00M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRNA is Buy with a score of 5.00.
